Market news

Shares of medical technology company Inspire Medical Systems (NYSE:INSP) jumped 7.4% in the morning session after Stifel analyst Jonathan Block raised the price target on the company to $80.00 from $75.00 while maintaining a Buy rating.

Inspire Medical Systems currently trades at $62.14 per share and has shown little upside over the past six months, posting a small loss of 3.4%. The stock also fell short of the S&P 500’s 11.7% gain during that period.

Detailed price information for Inspire Medical Systems Inc (INSP-N) from The Globe and Mail including charting and trades.

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Inspire is scheduled to present at 1:30 p.m. Eastern Time. The presentation will be accessible

Coryell Health otolaryngologist Dr. Bradford Holland has performed his 100th Inspire® procedure to help treat Central Texans' obstructive sleep apnea.

Detailed price information for CVS Corp (CVS-N) from The Globe and Mail including charting and trades.

Inspire Medical Systems stock has had a difficult run over the past three years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a discount to their estimated worth. Shareholders have seen the stock decline 73.6% over the past three years, which puts the current valuation in sharp focus for anyone still holding or looking at the company fresh. The recent announcement of a new growth plan, alongside higher revenue...

The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.

Inspire Medical Systems’ second quarter results were marked by improved coding clarity and cost discipline, which management credited as key drivers behind the company’s outperformance versus Wall Street expectations. Despite a year-on-year revenue decline, CEO Tim Herbert pointed to effective navigation of the evolving reimbursement landscape as a critical factor, stating the company delivered “adjusted operating income and positive cash flow ahead of expectations through continued disciplined

Motley Fool Press Release.

Detailed price information for Inspire Medical Systems Inc (INSP-N) from The Globe and Mail including charting and trades.

Inspire Medical raised its 2026 outlook after a Q2 beat, as Inspire V mix and cost control offset weak U.S. procedure activity.

Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.

Inspire Medical Systems (INSP) has an average rating of hold and mean price target of $57.21, accord

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.

Why Are Inspire Medical Systems (INSP) Shares Soaring Today

Moby summary of Inspire Medical Systems, Inc.'s Q2 2026 earnings call

INSPI beats expectations, raises FY26 guidance. Analysts raise price targets to $59 & $60. Stock jumps 14.6% in pre-market trading. #INSP

Why Inspire Medical Systems stock moved on Q2 earnings and guidance Inspire Medical Systems (INSP) caught investor attention after Q2 results that topped revenue and earnings expectations despite a year over year decline tied to coding and reimbursement disruptions. The company raised its full year revenue and EPS guidance and introduced Project Horizon, a restructuring plan designed to free up about US$30 million for growth investment. The market responded positively to management’s...

Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly revenue of US$200.58 million and earnings of US$0.14 per share that exceeded analyst expectations despite a year-on-year decline. Alongside these governance changes, Inspire raised its full-year outlook and launched Project Horizon, aimed at unlocking US$30 million in annualized investment...

Inspire Medical Systems (INSP) has an average rating of hold and mean price target of $57.21, accord

Despite a 7.6% revenue decline from coding disruptions, the company raises its full-year outlook and unveils Project Horizon to drive future growth.

Inspire (INSP) delivered earnings and revenue surprises of +163.64% and +2.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 7.6% year on year to $200.6 million. The company’s full-year revenue guidance of $855 million at the midpoint came in 1.4% above analysts’ estimates. Its non-GAAP profit of $0.14 per share was significantly above analysts’ consensus estimates.

Inspire Medical Systems (INSP) reported Q2 adjusted earnings late Monday of $0.14 per diluted share,

Generated second quarter revenue of $200.6 millionSecond quarter diluted EPS of $0.01; adjusted diluted EPS of $0.14Second quarter operating cash flow of $23.2 millionAnnounced strategic growth plan designed to unlock and redeploy $30 million for growth initiatives MINNEAPOLIS, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solut

Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting

The headline numbers for Inspire (INSP) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Medical technology company Inspire Medical Systems (NYSE:INSP) will be announcing earnings results this Monday after the bell. Here’s what to expect.

Inspire Medical Systems (INSP) has an average rating of Hold and mean price target of $51.43, accord